DEADLINE ALERT: Brower Piven Notifies Shareholders of October 3, 2016 Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess of $100,000 From Investment In Keryx Pharmaceuticals, Inc. To Contact The Firm - KERX

STEVENSON, Md., Sept. 27, 2016 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Keryx Pharmaceuticals, Inc. (NASDAQ:KERX) (“Keryx” or the “Company”) securities during the period between February 25, 2016, and August 1, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until October 3, 2016 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Keryx securities during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company was experiencing production-related difficulties in converting active pharmaceutical ingredient (“API”) to a finished drug product (Auryxia tablets), that the issue was resulting in decreased production yields of Auryxia tablets and that the Company would, and did, exhaust its reserve of finished drug product.

According to the complaint, following an August 1, 2016 announcement that the Company had determined that a supply interruption of Auryxia tablets was going to occur due to production-related issues in converting API to a finished drug product at its contract manufacturer, that the issue had resulted in variable production yields of finished drug product, and the Company had exhausted its reserve of finished drug product, the value of Keryx shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Keryx securities purchased on or after February 25, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.

CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]